$156 Million is the total value of Nan Fung Group Holdings Ltd's 43 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | KARUNA THERAPEUTICS INC | $48,940,443 | +19.4% | 225,688 | 0.0% | 31.28% | +12.1% | |
| ILMN | ILLUMINA INC | $22,348,058 | -19.4% | 119,196 | 0.0% | 14.28% | -24.3% | |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $12,973,321 | +7.8% | 368,665 | 0.0% | 8.29% | +1.2% | |
| SGEN | SEAGEN INC | $9,064,096 | -4.9% | 47,096 | 0.0% | 5.79% | -10.7% | |
| OCULIS HOLDING AGordinary shares | $8,028,063 | +65.9% | 651,100 | 0.0% | 5.13% | +55.9% | ||
| EXSCIENTIA PLCads | $5,090,561 | +11.7% | 859,892 | 0.0% | 3.25% | +4.9% | ||
| ISEE | IVERIC BIO INC | $4,405,451 | +61.7% | 111,984 | 0.0% | 2.82% | +51.9% | |
| XENE | XENON PHARMACEUTICALS INC | $4,403,630 | +7.6% | 114,380 | 0.0% | 2.81% | +1.0% | |
| KDNY | CHINOOK THERAPEUTICS INC | $4,377,959 | +66.0% | 113,950 | 0.0% | 2.80% | +55.9% | |
| REPL | Sell | REPLIMUNE GROUP INC | $4,289,640 | +28.3% | 184,739 | -2.4% | 2.74% | +20.5% |
| MRUS | MERUS N V | $3,975,830 | +43.1% | 151,000 | 0.0% | 2.54% | +34.4% | |
| SOMALOGIC INC | $3,919,049 | -9.4% | 1,696,558 | 0.0% | 2.50% | -14.9% | ||
| BGNE | BEIGENE LTDsponsored adr | $2,143,523 | -17.3% | 12,022 | 0.0% | 1.37% | -22.3% | |
| RANI THERAPEUTICS HLDGS INC | $2,033,566 | -20.2% | 493,584 | 0.0% | 1.30% | -25.0% | ||
| INCY | Sell | INCYTE CORP | $1,993,370 | -19.8% | 32,022 | -6.9% | 1.27% | -24.7% |
| GRTX | GALERA THERAPEUTICS INC | $1,913,256 | +21.9% | 613,223 | 0.0% | 1.22% | +14.5% | |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $1,842,480 | +197.8% | 204,720 | +160.1% | 1.18% | +179.8% |
| PACB | PACIFIC BIOSCIENCES CALIF IN | $1,817,512 | +14.9% | 136,655 | 0.0% | 1.16% | +7.9% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $1,493,699 | -7.9% | 1,166,952 | 0.0% | 0.96% | -13.5% | |
| GERN | New | GERON CORP | $1,245,480 | – | 388,000 | +100.0% | 0.80% | – |
| EXEL | EXELIXIS INC | $1,226,862 | -1.5% | 64,200 | 0.0% | 0.78% | -7.5% | |
| BMEA | Sell | BIOMEA FUSION INC | $878,000 | -52.8% | 40,000 | -33.3% | 0.56% | -55.7% |
| AVTE | AEROVATE THERAPEUTICS INC | $822,102 | -15.0% | 47,936 | 0.0% | 0.52% | -20.2% | |
| Sell | ENTRADA THERAPEUTICS INC | $743,101 | -30.4% | 49,082 | -33.3% | 0.48% | -34.6% | |
| EARGO INC | $729,167 | +5.3% | 147,904 | 0.0% | 0.47% | -1.1% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $718,117 | +27.3% | 29,984 | 0.0% | 0.46% | +19.5% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $704,805 | +12.4% | 370,950 | 0.0% | 0.45% | +5.4% | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $660,754 | +13.9% | 40,070 | +23.2% | 0.42% | +6.8% |
| ARGX | ARGENX SEsponsored adr | $557,314 | +4.6% | 1,430 | 0.0% | 0.36% | -1.9% | |
| CABA | New | CABALETTA BIO INC | $530,898 | – | 41,123 | +100.0% | 0.34% | – |
| Sell | GITLAB INC | $353,170 | -72.1% | 6,910 | -81.3% | 0.23% | -73.8% | |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $336,468 | – | 3,300 | +100.0% | 0.22% | – |
| ALXO | ALX ONCOLOGY HLDGS INC | $315,045 | +66.2% | 41,950 | 0.0% | 0.20% | +55.8% | |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $313,348 | -55.3% | 3,615 | -49.9% | 0.20% | -58.1% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $273,042 | -4.6% | 1,182 | 0.0% | 0.18% | -10.3% | |
| AFMD | AFFIMED N V | $222,813 | -19.8% | 372,472 | 0.0% | 0.14% | -24.9% | |
| AKRO | New | AKERO THERAPEUTICS INC | $206,603 | – | 4,425 | +100.0% | 0.13% | – |
| FGEN | Buy | FIBROGEN INC | $167,686 | -73.7% | 62,106 | +82.1% | 0.11% | -75.3% |
| KOD | KODIAK SCIENCES INC | $135,392 | +11.3% | 19,622 | 0.0% | 0.09% | +4.8% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $125,643 | -15.6% | 17,847 | 0.0% | 0.08% | -20.8% | |
| ABCL | ABCELLERA BIOLOGICS INC | $80,886 | -14.3% | 12,521 | 0.0% | 0.05% | -18.8% | |
| ATHA | New | ATHIRA PHARMA INC | $34,719 | – | 11,769 | +100.0% | 0.02% | – |
| CERS | CERUS CORP | $34,863 | -17.2% | 14,172 | 0.0% | 0.02% | -24.1% | |
| NVTA | Exit | INVITAE CORP | $0 | – | -11,337 | -100.0% | -0.01% | – |
| NRIX | Exit | NURIX THERAPEUTICS INC | $0 | – | -11,500 | -100.0% | -0.07% | – |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -177,900 | -100.0% | -0.08% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -4,168 | -100.0% | -0.30% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -25,606 | -100.0% | -0.39% | – |
| MELI | Exit | MERCADOLIBRE INC | $0 | – | -904 | -100.0% | -0.81% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.